Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aridis Pharmaceuticals Inc (ARDS)

Aridis Pharmaceuticals Inc (ARDS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,948
  • Shares Outstanding, K 47,929
  • Annual Sales, $ 3,090 K
  • Annual Income, $ -30,370 K
  • 60-Month Beta 1.00
  • Price/Sales 0.13
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ARDS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.18
  • Most Recent Earnings $-0.02 on 11/06/23
  • Latest Earnings Date 01/01/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +454,190.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0600 unch
on 04/19/24
0.0799 -24.91%
on 04/04/24
-0.0199 (-24.91%)
since 03/19/24
3-Month
0.0600 unch
on 04/19/24
0.0930 -35.48%
on 01/22/24
-0.0248 (-29.25%)
since 01/19/24
52-Week
0.0500 +20.00%
on 10/17/23
0.5395 -88.88%
on 05/31/23
-0.1658 (-73.43%)
since 04/19/23

Most Recent Stories

More News
FDA Provides Positive Feedback for Aridis Pharmaceuticals’ (NASDAQ: ARDS) AR-301 Phase 3 Study

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) receives encouraging input from the FDA for the proposed confirmatory Phase 3 trial of AR-301,

ARDS : 0.0600 (-2.44%)
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More

Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.

GSK : 39.75 (+1.22%)
SGEN : 228.74 (-0.07%)
ACAD : 16.82 (-1.46%)
MRSN : 3.25 (-2.69%)
ARDS : 0.0600 (-2.44%)
Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals

Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.

CRSP : 55.05 (-1.98%)
KALA : 6.59 (-3.23%)
ARDS : 0.0600 (-2.44%)
ALLO : 3.47 (+0.29%)
Here's Why Aridis Pharmaceuticals (ARDS) Is a Great 'Buy the Bottom' Stock Now

After losing some value lately, a hammer chart pattern has been formed for Aridis Pharmaceuticals (ARDS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate...

ARDS : 0.0600 (-2.44%)
Biotech Pops On New Patient Enrollment Announcement

A California-based %Biotech company turned heads on Wednesday after the company announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a...

ARDS : 0.0600 (-2.44%)
Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

ARDS : 0.0600 (-2.44%)
KMDA : 5.05 (-0.98%)
Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 42.11% and 96.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AFMD : 5.15 (+1.58%)
ARDS : 0.0600 (-2.44%)
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

SPRO : 1.4000 (-4.76%)
ARDS : 0.0600 (-2.44%)
Qiagen (QGEN) Tops Q3 Earnings and Revenue Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 17.78% and 4.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

QGEN : 40.00 (+1.34%)
ARDS : 0.0600 (-2.44%)
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 6.90% and 99.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

EDIT : 5.49 (-1.08%)
ARDS : 0.0600 (-2.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 0.0715
2nd Resistance Point 0.0692
1st Resistance Point 0.0646
Last Price 0.0600
1st Support Level 0.0577
2nd Support Level 0.0554
3rd Support Level 0.0508

See More

52-Week High 0.5395
Fibonacci 61.8% 0.3525
Fibonacci 50% 0.2948
Fibonacci 38.2% 0.2370
Last Price 0.0600
52-Week Low 0.0500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar